(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 2 351 742 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 43

(48) Corrigendum issued on:
21.09.2011 Bulletin 2011/38

(43) Date of publication:
03.08.2011 Bulletin 2011/31

(21) Application number: **09819103.4**

(22) Date of filing: **29.09.2009**

(51) Int Cl.:
C07D 231/56 *(2006.01)* ***A61K 31/416*** *(2006.01)*
A61P 13/10 *(2006.01)* ***A61P 43/00*** *(2006.01)*

(86) International application number:
PCT/JP2009/066895

(87) International publication number:
WO 2010/041568 (15.04.2010 Gazette 2010/15)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: **09.10.2008 US 104024**

(71) Applicant: **Asahi Kasei Pharma Corporation**
Tokyo 101-8101 (JP)

(72) Inventors:
- **NAKANO Seiji**
  Tokyo 101-8101 (JP)
- **MORIMOTO Akifumi**
  Tokyo 101-8101 (JP)
- **WADA Yasuhiro**
  Tokyo 101-8101 (JP)

(74) Representative: **Forstmeyer, Dietmar et al**
BOETERS & LIECK
Oberanger 32
80331 München (DE)

(54) INDAZOLE DERIVATIVE

(57) Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a β3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc.

EP 2 351 742 A8